Serotonin Reuptake Inhibitor
Pain Reactivity in 2-Month-Old Infants After Prenatal and Postnatal Selective Serotonin Reuptake Inhibitor Medication Exposure
17
Efficacy of selective serotonin reuptake inhibitor (SSRI) in patient with premature ejaculation
5
Bioimpedance in monitoring of effects of selective serotonin reuptake inhibitor treatment
6
Validation of an UPLC-MS/MS method for simultaneous Quantification of two Selective Serotonin and nor Epinephrine Reuptake Inhibitors and one Selective Serotonin Reuptake Inhibitor in human plasma
10
Maternal Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Newborn Neurobehavior
10
Behavioral destabilization induced by the selective serotonin reuptake inhibitor fluoxetine
11
Findings From Selective Serotonin Reuptake Inhibitor–Exposed Neonates Should Be Interpreted With Caution
5
Prestroke selective serotonin reuptake inhibitor use and functional outcomes after ischaemic stroke
8
<p>Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives</p>
8
Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder
7
Hippocampal Endoplasmic Reticulum Stress: Novel Target in PTSD Pharmacotherapy?
6
Neonatal S100B Protein Levels After Prenatal Exposure to Selective Serotonin Reuptake Inhibitors
11
Should Selective Serotonin Reuptake Inhibitors Be Prescribed for Children With Major Depressive and Anxiety Disorders?
6
Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients
7
Antidepressant treatment response is modulated by genetic and environmental factors and their interactions
9
Antenatal Use of Selective Serotonin-Reuptake Inhibitors and QT Interval Prolongation in Newborns
8
Potential drug therapies for the treatment of fibromyalgia
37
Clinical use of antidepressant therapy and associated cardiovascular risk
9
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
15
Post-marketing observational program of the effectiveness of fluvoxamine for the treatment of depression in patients with neurological disorders: the FRIENDS study
10